Abstract. Floxacrine was a promising antimalarial compound that led to the identification of WR 243251. On the basis of their structures, we suspected that these compounds might be good inhibitors of hematin polymerization. Indeed, WR 243251 was as potent and floxacrine was only 2-fold less potent than chloroquine as inhibitors of this process. However, this hematin polymerization inhibition did not completely account for the increased antimalarial potency of WR 243251 versus chloroquine. The WR 243251 ketone hydrolysis product WR 243246 was without activity against hematin polymerization. These data also confirm that hematin polymerization inhibition can be quite sensitive to small changes in inhibitor structure.
The novel antimalarial dihydroacridinedione floxacrine 1 was a promising lead with causal prophylactic activity, but unfortunately, it had several liabilities, including limited water solubility, 2 parasite drug resistance, 3, 4 and dose-dependent chronic periarteritis. 4 This situation led to substantial and well-documented 2,5-7 efforts to identify an analog of floxacrine without these drawbacks. The chemical structure to emerge from this work was a deshydroxy-1-imino derivative of floxacrine, WR 243251, 2,7 a quinacrine-floxacrine hybrid ( Figure 1 ) devoid of the vascular cardiotoxicity of floxacrine. As increasing evidence 8, 9 suggests that quinoline and acridine antimalarials act by inhibition of hematin polymerization, we wished to determine if floxacrine and WR 243251 might exert their antimalarial activity by the same mechanism.
Plasmodium falciparum strains NF54 and K1 were cultured by use of asynchronous stock cultures as previously described. 10 Hematin polymerization reactions were carried out as previously described 8, 10 by using 14 C-hemin at pH 4.8. An acetonitrile extract of P. falciparum trophozoite lysate was used to initiate the reactions. Compounds were added to the reaction mixture as dimethyl sulfoxide (DMSO) solutions up to a maximum DMSO concentration of 10%. The dpm values obtained from triplicate assays were expressed as percentage inhibition relative to hemozoin formation in a drug-free control. The values of triplicate assays were plotted semilogarithmically, and the 50% inhibitory concentration values (M) were calculated graphically Ϯ standard deviation (Table 1) .
WR 243251 and its ketone hydrolysis product and potential metabolite WR 243246 were good inhibitors of parasite growth, whereas floxacrine was an order of magnitude less potent, consistent with existing in vitro data. 5, 11 Floxacrine, WR 243251, and WR 243246 were only 2-to 3-fold less potent against the chloroquine-resistant K1 versus the chloroquine-sensitive NF54 strain compared with chloroquine's 26-fold potency differential against these 2 strains.
As inhibitors of hematin polymerization, WR 243251 was as potent and floxacrine was 2-fold less potent than chloroquine. In contrast, WR 243246 was without activity against this process. Because the structures of WR 243246 and floxacrine differ only in that WR 243246 is a 10-desoxy derivative of floxacrine with a different C-3 phenyl substitution pattern, these data indicate a significant structural specificity for inhibition of hematin polymerization.
The hematin polymerization inhibition data does not completely account for the increased antimalarial potency of WR 243251 versus chloroquine and indicates that WR 243246, and possibly floxacrine, exert their antimalarial activity by other mechanisms. As hematin polymerization takes place in the food vacuole, 10 whether the monoprotic WR 243251 inhibits this process in the parasite would likely depend on whether it binds to hematin (ferriprotoporphyrin IX) and is concentrated in this parasite organelle, 8, 12 as are the monoand diprotic weak bases quinine and chloroquine. 9, 13, 14 In summary, we have provided what to our knowledge is the first evidence that WR 243251 may exert its antimalarial activity by inhibition of hematin polymerization. Of course, it is also possible that WR 243251 acts by different mechanisms, such as inhibition of P. falciparum respiratory pathways (Suswam EA and others, unpublished data). As illustrated by the data for floxacrine and WR 243246, it is evident that hematin polymerization inhibition can be quite sensitive to small changes in inhibitor structure, as is also apparent for chloroquine and its analogs. 15, 16 Financial support: This work was supported in part by U.S. National Institutes of Health grant AI39670-01. 
